SCHEMBL23317645

SCHEMBL23317645

Cc1cc(F)cc(C)c1NC(=O)C(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.45
LCK P06239 1/20 0.44
USP2 O75604 1/20 0.41
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40
ALOX12 P18054 1/20 0.40
SOAT1 P35610 1/20 0.40
ABL1 P00519 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 2/20 0.38
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
PDK1 Q15118 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK3 Q15120 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25311825 0.81 HTT (0.57) HTTL3MBTL1LCKUSP2ALDH1A1
SCHEMBL21636894 0.80 HTT (0.41) HTTL3MBTL1ALDH1A1LMNAALOX12
SCHEMBL18622119 0.80 HTT (0.61) HTTL3MBTL1LCKUSP2ALDH1A1
SCHEMBL18415511 0.79 ALDH1A1 (0.61) L3MBTL1ALDH1A1LMNARAB9ANPC1
SCHEMBL23317289 0.78 HTT (0.54) HTTL3MBTL1LCKUSP2ALDH1A1
SCHEMBL22430520 0.78 HPGD (0.51) LCKALDH1A1LMNAGAAHPGD
SCHEMBL5342999 0.78 HTT (0.54) HTTL3MBTL1LCKUSP2ALDH1A1
SCHEMBL23317519 0.77 HTT (0.53) HTTL3MBTL1LCKUSP2ALDH1A1
SCHEMBL901118 0.76 L3MBTL1 (0.54) HTTL3MBTL1USP2ALDH1A1LMNA
SCHEMBL12666584 0.76 L3MBTL1 (0.59) L3MBTL1LCKALDH1A1LMNAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701370-B2 Phosphonium ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11701370-B2 Phosphonium ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-20210128589-A1 PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE Nocion Therapeutics, Inc. 2021-05-06 US disclosed
US-20210130380-A1 PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE Nocion Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130380-A1 PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE TRPV1, TRPV5, TRPA1 HTT 4183/4885L3MBTL1 4848/4885LCK 197/4885
US-20210128589-A1 PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE TRPV1, TRPV5, TRPA1 HTT 4183/4885L3MBTL1 4848/4885LCK 197/4885
US-11701370-B2 Phosphonium ion channel blockers and methods for use TRPV1, TRPV5, TRPA1 HTT 4183/4885L3MBTL1 4848/4885LCK 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.